Vanda Pharmaceuticals Inc is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies. With a focus on addressing unmet medical needs, Vanda Pharmaceuticals is dedicated to providing effective treatment options for patients worldwide. The company prides itself on its commitment to scientific excellence, ethical practices, and patient-centric values. By leveraging its extensive expertise in neuroscience and clinical development, Vanda Pharmaceuticals aims to improve the lives of individuals suffering from central nervous system disorders. With its passion for innovation and dedication to improving patient outcomes, Vanda Pharmaceuticals Inc embodies a strong corporate philosophy centered on advancing healthcare solutions.

Vanda Pharmaceuticals Inc is primarily present in the United States.

Vanda Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for Fanapt®, an antipsychotic medication, in 2009. In 2013, they gained FDA approval for Hetlioz®, a treatment for Non-24-Hour Sleep-Wake Disorder. Vanda Pharmaceuticals has also actively developed partnerships, such as their collaboration with Novartis to commercialize Fanapt® in the US. As a global biopharmaceutical company, Vanda Pharmaceuticals Inc continues to advance research and development for innovative therapies, aiming to improve patients' lives.

Vanda Pharmaceuticals Inc. is a renowned biopharmaceutical company with a rich history and impressive background. Founded in 2002 and headquartered in Washington, D.C., Vanda Pharmaceuticals Inc. focuses on the development and commercialization of innovative therapies to address critical medical needs. Leveraging their expertise in clinical development, the company has successfully brought several groundbreaking products to market, particularly in the fields of neurology and psychiatry. With a strong commitment to improving patient outcomes, Vanda Pharmaceuticals Inc. continues to invest in research and development to pioneer new treatment options and enhance the lives of individuals worldwide.

The main competitors of Vanda Pharmaceuticals Inc in the market include companies like Novartis AG, Jazz Pharmaceuticals, and Supernus Pharmaceuticals.

Vanda Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Vanda Pharmaceuticals Inc is focused on developing, commercializing, and marketing pharmaceutical products. As a biopharmaceutical company, Vanda Pharmaceuticals specializes in the discovery and development of innovative therapies to address unmet medical needs. With a strategic focus on central nervous system disorders, Vanda Pharmaceuticals aims to deliver effective treatments that improve the lives of patients. Through research, clinical trials, and product commercialization, Vanda Pharmaceuticals strives to bring novel and differentiated therapeutic options to the market.

مُعامل القيمة السوقية إلى الأرباح لـ Vanda Pharmaceuticals هو ؜-٣٫٥٦.

مُعامِل القيمة إلى المبيعات Vanda Pharmaceuticals هو ١٫٠٤.

نقاط جودة AlleAktien لـ Vanda Pharmaceuticals هي 3/10.

المتوقعة Vanda Pharmaceuticals الإيرادات هي ٢٢٧٫٣١ مليون. USD.

صافي الربح المتوقعة Vanda Pharmaceuticals هو ؜-٦٦٫٦٢ مليون. USD.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development, manufacturing, and marketing of innovative drugs for patients with central nervous system (CNS) disorders. The company is headquartered in Washington, D.C., USA, and operates worldwide. Vanda's product portfolio currently includes two prescription drugs used to treat sleep disorders and severe psychiatric disorders. The first of these medications is a product called Fanapt, which is approved for the treatment of schizophrenia in adults. It is an atypical antipsychotic that targets the neurotransmitter dopamine and helps reduce unusual perceptions and hallucinations. The second medication is a sleep aid called Hetlioz, which is approved for the treatment of Non-24-Hour Sleep-Wake Rhythm Disorder (Non-24) in blind individuals. Hetlioz regulates circadian rhythms that help our bodies recognize day and night cycles. People with Non-24 have difficulty recognizing and adhering to these rhythms, leading to insomnia and daytime sleepiness. Vanda Pharmaceuticals is also working on the development of other drugs, including a medication called Tradipitant for the treatment of chronic pruritus and a medication called Vanda073 for the treatment of epilepsy. Both drugs are currently in different stages of clinical development. Vanda Pharmaceuticals' business model is based on the development of innovative drugs that have a high medical need and significant market potential. The company is dedicated to developing and bringing new therapies to the market for CNS disorders to improve patients' lives and provide value to shareholders. As part of its strategy to achieve these goals, the company has formed partnerships with other pharmaceutical companies to accelerate the development and marketing of its products. Furthermore, Vanda has established a strong presence in the US and Europe and continuously works to protect its intellectual property and conduct clinical trials to obtain market approval for its drugs. Overall, Vanda Pharmaceuticals has carved out a niche in the pharmaceutical market by specializing in the development of drugs for CNS disorders. With the introduction of Hetlioz and Fanapt, the company has already achieved significant successes and has other exciting products in its development pipeline. With its strong presence in the US and Europe and strategic partnerships, Vanda has a promising future as an innovative biopharmaceutical company.

يوزع Vanda Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Vanda Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـVanda Pharmaceuticals هو US9216591084.

رمز WKN لـ Vanda Pharmaceuticals هو A0JJT3.

الرمز المُختصر لـ Vanda Pharmaceuticals هو VNDA.

خلال آخر 12 شهراً، دفعت Vanda Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Vanda Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Vanda Pharmaceuticals هي .

Vanda Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Vanda Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Vanda Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Vanda Pharmaceuticals المُعلن عنها في ٥‏/٤‏/٢٠٢٥، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٥‏/٤‏/٢٠٢٥.

تم توزيع آخر دفعة من الأرباح بتاريخ ٥‏/٤‏/٢٠٢٥.

في العام 2024، وزعت Vanda Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Vanda Pharmaceuticals بالعملة USD.